题名

腫瘤壞死因子－α抑制劑治療非感染性葡萄膜炎

DOI

10.6666/ClinMed.202006_85(6).0060

作者

趙育箴

关键词

非感染性葡萄膜炎（non-infectious uveitis） ； 生物製劑（biologic agent） ； 腫瘤壞死因子-α抑制劑（anti-TNF-α therapy, TNF-α inhibitor, TNF-α抑制劑）

期刊名称

臨床醫學月刊

卷期/出版年月

85卷6期（2020 / 06 / 26）

页次

330 - 333

内容语文

繁體中文
中文摘要

頑固型非感染性葡萄膜炎的治療初期會使用類固醇，其次會加上免疫抑制劑如Cyclosporin, Azathioprine, Methotrexate, Mycophenolate等，但若發炎仍無法獲得緩解，則會使用生物製劑，目前臺灣較常用於治療非感染性葡萄膜炎的生物製劑為Adalimumab（復邁，Humira®），是一種腫瘤壞死因子-α抑制劑（tumor necrosis factor-alpha inhibitor, TNF-α inhibitor），是目前臺灣對於葡萄膜炎的治療唯一有通過適應症的生物製劑。其他TNF-α抑制劑包含Infliximab, Golimumab，和Certolizumab。而其他不同機轉的生物製劑包含抗CD20單株抗體（如Rituximab），抗白細胞介素抗體（interleukin receptor antagonist，如Anakinra和Tocilizumab），及干擾素（interferon）等，在臺灣治療葡萄膜炎的使用經驗相對較少。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Cordero-Coma, M,Sobrin, L(2015).Antitumor necrosis factor-α therapy in uveitis.Surv Ophthalmol,60,575-589.
  2. Lee, S,Park, YJ,Lee, JY(2019).The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis.J Korean Med Sci,34,e278.
  3. Lejoyeux, R,Diwo, E,Vallet, H(2018).Infliximab and adalimumab in uveitic macular edema.Ocul Immunol Inflamm,26,991-996.
  4. Lopalco, G,Emmi, G,Gentileschi, S(2017).Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study.Modern Rheumatology,27,1031-1035.
  5. Mengi, A,Özdolap, Ş,Oray, HS(2019).Recurrent uveitis under golimumab treatment in a patient diagnosed with axial spondyloarthritis: Is it a paradoxical effect?.Turk J Phys Med Rehabil,65,191-193.
  6. Mitoma, H,Horiuchi, T,Tsukamoto, H(2018).Molecular mechanisms of action of anti-TNF-α agents- Comparison among therapeutic TNF-a antagonists.Cytokine,101,56-63.
  7. Moisseiev, E,Shulman, S.(2014).Certolizumab-induced uveitis: a case report and review of the literature.Case Rep Ophthalmol,5,54-59.
  8. Raffeiner, B,Ometto, F,Bernardi, L(2014).Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept.Case Rep Med,2014,471319.
  9. Sfikakis, PP,Theodossiadis, PG,Katsiari, CG(2001).Effect of infliximab on sight-threatening panuveitis in Behçet's disease.Lancet,358,295-296.
  10. Suhler, EB,Adan, A,Brezin, AP(2018).Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study:VISUAL III.Ophthalmology,125,1075-1087.
  11. Tabbara, KF,Al-Hemidan, AI(2008).Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.Am J Ophthalmol,146,845-850.
  12. van Denderen, JC,Visman, IM,Nurmohamed, MT(2014).Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis.J Rheumatol,41,1843-1848.
  13. Wendling, D,Paccou, J,Berthelot, JM(2011).New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.Semin Arthritis Rheum,41,503-510.
print cancel